SCS Traditional denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for scs traditional are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Quantity Limits to Traditional SCS

Humana's coverage policy for spinal cord stimulation specifies limits on the components, phases, and episodes of care that will be authorized — including the number of trial phases, the transition from trial to permanent implant, the number of leads or extensions, and, in some cases, the frequency of battery replacements or system upgrades. A quantity-limits denial typically means the submitted request exceeded the authorized component count, sought a second trial without documented justification, or requested replacement hardware within a lookback period that does not yet meet Humana's replacement threshold.

## Why This Denial Is Appealable

Quantity limits in device coverage are not absolute. Humana's own policy — and applicable law — preserves the right to appeal when the clinical circumstances justify exceeding the standard quantity. If your physician has documented a clinical reason for the additional component, phase, or replacement (e.g., lead migration confirmed on imaging, device failure with supporting technical documentation, clinical non-response at a prior parameter set requiring a new trial), that documentation forms the basis for a medical-necessity exception to the quantity limit.

## Your Federal Appeal Rights

• Internal appeal: File a written appeal under ERISA §503 or Humana's grievance procedures. Request the specific quantity-limit provision cited and the clinical rationale for applying it to your case.
• External review (ACA §2719): Quantity-limit denials grounded in medical-necessity criteria are eligible for binding independent external review. The external-review window is generally up to four months from the denial notice — verify on your Explanation of Benefits.
• Expedited review: Available for urgent clinical situations, such as an ongoing SCS trial with an imminent implant decision window.

## Documentation to Gather

1. Clinical justification for the additional quantity — imaging reports, device interrogation logs, or office notes documenting the specific clinical reason the standard quantity is insufficient (e.g., lead displacement confirmed on X-ray, inadequate coverage of pain territory with standard lead count). 2. Device and implant history — dates of prior SCS trial(s), permanent implant, any prior revisions, and clinical outcomes at each stage. 3. Prescriber letter — an explicit statement from the implanting physician explaining why the additional component, phase, or replacement is the minimum necessary to achieve the clinical goal, referencing the device's FDA-approved labeling and Humana's coverage criteria. 4. Humana coverage policy — obtain the specific quantity-limit provision and any exception language; confirm whether your clinical situation falls within or outside the stated limit, and identify the exception pathway. 5. FDA device labeling — confirm that the requested configuration is consistent with the FDA-approved IFU.

## Criteria-Mapping Approach

In your appeal, quote the exact quantity-limit language from Humana's SCS coverage policy. Then create a clinical-exception section: state the standard limit, state the quantity requested, and cite each piece of documentation establishing why the clinical circumstance makes the additional quantity medically necessary rather than elective or duplicative. Attach imaging or technical records as labeled exhibits to make the clinical justification concrete and verifiable.